About Us
Executive Director, Chief Executive Officer: Mr. Eric Tse
-
- Executive Director, Chief Executive Officer: Mr. Eric Tse
- Mr. Eric Tse was appointed as an Executive Director of Sino Biopharmaceutical Limited in 2019, the Chairman of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in 2020, and the Chief Executive Officer of Sino Biopharmaceutical Limited and Chairman of Beijing Tide Pharmaceutical Co., Ltd. in 2022. He holds a Bachelor degree in Economics from the Wharton School of the University of Pennsylvania, a Master's degree in Management and Global Leadership from Schwarzman College, Tsinghua University, and is a Ph.D. candidate in Social and Administrative Pharmacy at China Pharmaceutical University. He was awarded the "Top 10 Outstanding Chinese American Youth" and the "Advanced Individual of the Outstanding Contribution to Manufacture in Jiangsu Award".
Mr. Eric Tse is currently a member of the Beijing Municipal Committee of the CPPCC, a member of All-China Youth Federation, a Vice Chairman of the 12th Committee of the Shaanxi Youth Federation, a member of the 7th Election Committee of the Hong Kong SAR, a vice president of the Youth Federation of Hong Kong Political Consultative Conference, a member of the Digital Economy Committee of the APEC China Business Council, a member of the Presidium of Global Shapers under the World Economic Forum, a Vice Chairman of the Science and Technology Innovation Committee of the Belt and Road General Chamber of Commerce, a member of the Y.Elites Association, and an Executive Vice President of the Jiangsu Overseas Chinese Entrepreneurs Association.
Since taking over as Chief Executive Officer of Sino Biopharm, Mr. Tse has focused on the four main strategies of "organizational integration, comprehensive innovation, globalization, and digitalization". He leads the daily operations of the group, advances major decisions on corporate strategy, personnel appointments, investment and integration. Hr alsocomprehensively manages the Group's subsidiary companies. builds a professional management team,further enhances organizational efficiency, drives innovative business, connects external collaborations, and advances the Group's global innovation process, aiming to establish a Chinese international innovative pharmaceutical company. Under the leadership of Mr. Tse, the company is commited to the path of innovation and transformation, and building long-term core competitive advantages through comprehensive innovation. Sino Biopharm and its subsidiaries, such as Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Beijing Tide Pharmaceutical Co., Ltd., uphold the mission of " Enhancing Life Quality, Upholding Life Dignity". With a focus on societal clinical medication needs, they focus on the four major areas of oncology, liver diseases, respiratory, and surgery/analgesic. They advance internal innovation and business development in parallel, cultivate a new innovation ecosystem, develop world-leading innovative R&D capabilities, enhance the Group's core competitiveness with new quality productive forces, and continuously achieve outstanding accomplishments and innovative breakthroughs. The proportion of innovative drug R&D investment at Sino Biopharm has increased to 77% of total R&D investment. Currently, with more than 70 innovative drugs in the pipeline, with a forward-looking layout of multiple new targets, new platforms, and new technologies with blockbuster potential. In the next three years, more than 10 innovative drugs will be launched to serve patients. Leveraging the strong platform of Sino Biopharm, its subsidiaries Chia Tai Tianqing and Beijing Tide Pharmaceutical have developed steadily. For many consecutive years, they have been selected for authoritative industry lists such as the Top 100 Pharmaceutical Companies in China and the Best Industrial Enterprises for Pharmaceutical R&D Pipelines in China. They have undertaken more than 80 national and provincial science and technology projects and have received honors such as the "China Patent Gold Award" and the "National Science and Technology Progress Award".
While dedicated to corporate management, Mr. Eric Tse is passionate about and actively involved in youth work in Hong Kong and Chinese mainland. He continuously speaks up via the Hong Kong media on important topics such as Hong Kong's integration into the national development strategy, the steady and long-term implementation of "One Country, Two Systems", and promoting Hong Kong's transition "from governance to prosperity", contributing to the long-term prosperity, stability, and continued brilliance of Hong Kong.
*Portrait rights belong to the individual. Unauthorized use is prohibited.
